Who
Mahesh Krishnan
Director
Company insider
Files Form 4 as: Director, Halozyme Therapeutics; Director, Chinook Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 2 Apr 2022
- Last trade
- 29 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | $281K7,304 at $38.46 | filing |
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $548K7,304 at $75.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,304 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,304 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code M | $281K7,304 at $38.46 | filing |
| 29 Jun 2026filed 30 Jun 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $548K7,304 at $75.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,040 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,796 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 1 May 2025filed 2 May 2025 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,165 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,804 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,501 at $0.00 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | $619K26,600 at $23.26 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,401 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Chinook Therapeutics | SEC FORM 4 Code D | —1,275 | filing |
| 4 Apr 2023filed 4 Apr 2023 | Chinook Therapeutics | SEC FORM 4 Sold | $21K924 at $23.01 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Chinook Therapeuticsoption or derivative | SEC FORM 4 Code M | —2,199 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | Chinook Therapeutics | SEC FORM 4 Code M | —2,199 | filing |
News
No headline names them, or the companies they trade most, lately.